ALEXANDER MORGAN: Open Payments
NPI 1407465446 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$979 in 59 payments from 21 companies in 2025. Trend: 2023 $1,700 · 2024 $1,189 · 2025 $979
Food & beverage: $979
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $156 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 14 | $127 |
| Alnylam Pharmaceuticals Inc. | 2 | $82 |
| PFIZER INC. | 5 | $81 |
| ABIOMED | 3 | $60 |
| SCPHARMACEUTICALS INC. | 3 | $56 |
| Novartis Pharmaceuticals Corporation | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $52 |
| Amgen Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $31 |
Products named: LifeVest, ELIQUIS, ONPATTRO, Wegovy, FUROSCIX, LEQVIO, TRELEGY ELLIPTA, Ozempic.
Industry payments across MD — which companies pay providers there.
